Advaxis to Host Business Update Conference Call on November 2, 2018
October 26 2018 - 7:00AM
Business Wire
Advaxis, Inc. (NASDAQ:ADXS), a late-stage
biotechnology company focused on the discovery, development and
commercialization of immunotherapy products, announces that the
Company will host a business update call on Friday, November 2,
2018.
Advaxis’ senior management will host a conference call to
provide a business update and pipeline discussion. The conference
call and live audio webcast will begin at 11:00 a.m. Eastern time
on Friday, November 2, 2018.
Conference Call & Webcast
InformationWHEN: Friday, November 2, 2018 at 11:00 a.m.
Eastern timeDOMESTIC DIAL-IN: (844) 348-6133INTERNATIONAL DIAL-IN:
(631) 485-4564CONFERENCE ID: 1538717WEBCAST:
ir.advaxis.com/events-presentations
For those unable to participate in the live conference call or
webcast, a digital recording will be available beginning November
2, 2018 two hours after the close of the conference call. To access
the recording, please dial (855) 859-2056 (domestic) or (404)
537-3406 (international) and provide the operator with the
conference ID: 1538717. In addition, an audio webcast will be
archived on the Company’s website for a period of time at
www.advaxis.com.
About Advaxis, Inc.
Advaxis, Inc. is a late-stage biotechnology company focused on
the discovery, development and commercialization of
proprietary Lm-based antigen delivery products. These
immunotherapies are based on a platform technology that utilizes
live attenuated Listeria monocytogenes (Lm) bioengineered to
secrete antigen/adjuvant fusion proteins. These Lm-based
strains are believed to be a significant advancement in
immunotherapy as they integrate multiple functions into a single
immunotherapy and are designed to access and direct antigen
presenting cells to stimulate anti-tumor T cell immunity, activate
the immune system with the equivalent of multiple adjuvants, and
simultaneously reduce tumor protection in the tumor
microenvironment to enable the T cells to eliminate tumors. Advaxis
has four franchises in various stages of clinical and preclinical
development: HPV-associated cancers, personalized
neoantigen-directed immunotherapy, off-the-shelf, hotspot/cancer
antigens neoantigen-directed immunotherapy and prostate cancer.
To learn more about Advaxis, visit www.advaxis.com and connect
on Twitter, LinkedIn, Facebook and YouTube.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181026005039/en/
Investors:LHA Investor RelationsMiriam Weber Miller,
212-838-3777mmiller@lhai.comorAdvaxis, Inc.Ranya Dajani,
609-250-7559dajani@advaxis.com
Ayala Pharmaceuticals (QX) (USOTC:ADXS)
Historical Stock Chart
From Apr 2024 to May 2024
Ayala Pharmaceuticals (QX) (USOTC:ADXS)
Historical Stock Chart
From May 2023 to May 2024